| Douglas Arlyn Kinkel, MD | |
|
2450 S Telshor Blvd, Las Cruces, NM 88011-5069 | |
| (706) 354-5770 | |
| Not Available |
| Full Name | Douglas Arlyn Kinkel |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine - Emergency Medical Services |
| Location | 2450 S Telshor Blvd, Las Cruces, New Mexico |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417003377 | NPI | - | NPPES |
| 25445 | Medicaid | NM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207PE0004X | Emergency Medicine - Emergency Medical Services | 90-224 (New Mexico) | Primary |
| Entity Name | Emergency Staffing Solutions Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477590974 PECOS PAC ID: 9830001650 Enrollment ID: O20070724000197 |
News Archive
The drug Hydroxychloroquine has long been studied as a treatment for malaria and autoimmune diseases. When the coronavirus pandemic spread across the globe, many countries resorted to using the drug in the hopes that it would improve outcomes of hospitalized patients affected by the coronavirus disease (COVID-19).
Gilead Sciences, Inc. today announced topline results from a Phase 3 clinical trial (Study GS-US-334-0118) in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin (RBV) for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection.
Oncotarget published "The pro-apoptotic actions of 2-methoxyestradiol against ovarian cancer involve catalytic activation of PKCδ signaling" which reported that the authors have previously shown that a flaxseed-supplemented diet decreases both the incidence and severity of ovarian cancer in laying hens, also induces CYP1A1 expression in liver.
Intensifying current transplant conditioning to remove rather than suppress immune cells ahead of autologous haematopoietic stem cell transplantation may result in long-term remission of multiple sclerosis, phase II trial findings show.
Ambry Genetics today announces that it is the first laboratory to provide CLIA-approved exome services for applications in clinical diagnostics. After comprehensive review by Ambry's staff of geneticists and medical directors, these results will allow clinicians to diagnose affected patients with conditions that have eluded traditional diagnostic approaches.
› Verified 2 days ago
| Entity Name | Ess Hospitalist Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881967305 PECOS PAC ID: 6103085295 Enrollment ID: O20120718000719 |
News Archive
The drug Hydroxychloroquine has long been studied as a treatment for malaria and autoimmune diseases. When the coronavirus pandemic spread across the globe, many countries resorted to using the drug in the hopes that it would improve outcomes of hospitalized patients affected by the coronavirus disease (COVID-19).
Gilead Sciences, Inc. today announced topline results from a Phase 3 clinical trial (Study GS-US-334-0118) in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin (RBV) for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection.
Oncotarget published "The pro-apoptotic actions of 2-methoxyestradiol against ovarian cancer involve catalytic activation of PKCδ signaling" which reported that the authors have previously shown that a flaxseed-supplemented diet decreases both the incidence and severity of ovarian cancer in laying hens, also induces CYP1A1 expression in liver.
Intensifying current transplant conditioning to remove rather than suppress immune cells ahead of autologous haematopoietic stem cell transplantation may result in long-term remission of multiple sclerosis, phase II trial findings show.
Ambry Genetics today announces that it is the first laboratory to provide CLIA-approved exome services for applications in clinical diagnostics. After comprehensive review by Ambry's staff of geneticists and medical directors, these results will allow clinicians to diagnose affected patients with conditions that have eluded traditional diagnostic approaches.
› Verified 2 days ago
| Entity Name | App Of New Mexico Ed Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891169942 PECOS PAC ID: 7416259445 Enrollment ID: O20160108000220 |
News Archive
The drug Hydroxychloroquine has long been studied as a treatment for malaria and autoimmune diseases. When the coronavirus pandemic spread across the globe, many countries resorted to using the drug in the hopes that it would improve outcomes of hospitalized patients affected by the coronavirus disease (COVID-19).
Gilead Sciences, Inc. today announced topline results from a Phase 3 clinical trial (Study GS-US-334-0118) in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin (RBV) for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection.
Oncotarget published "The pro-apoptotic actions of 2-methoxyestradiol against ovarian cancer involve catalytic activation of PKCδ signaling" which reported that the authors have previously shown that a flaxseed-supplemented diet decreases both the incidence and severity of ovarian cancer in laying hens, also induces CYP1A1 expression in liver.
Intensifying current transplant conditioning to remove rather than suppress immune cells ahead of autologous haematopoietic stem cell transplantation may result in long-term remission of multiple sclerosis, phase II trial findings show.
Ambry Genetics today announces that it is the first laboratory to provide CLIA-approved exome services for applications in clinical diagnostics. After comprehensive review by Ambry's staff of geneticists and medical directors, these results will allow clinicians to diagnose affected patients with conditions that have eluded traditional diagnostic approaches.
› Verified 2 days ago
| Entity Name | Fedko Emergency Physicians New Mexico, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770047441 PECOS PAC ID: 4880934389 Enrollment ID: O20190320001146 |
News Archive
The drug Hydroxychloroquine has long been studied as a treatment for malaria and autoimmune diseases. When the coronavirus pandemic spread across the globe, many countries resorted to using the drug in the hopes that it would improve outcomes of hospitalized patients affected by the coronavirus disease (COVID-19).
Gilead Sciences, Inc. today announced topline results from a Phase 3 clinical trial (Study GS-US-334-0118) in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin (RBV) for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection.
Oncotarget published "The pro-apoptotic actions of 2-methoxyestradiol against ovarian cancer involve catalytic activation of PKCδ signaling" which reported that the authors have previously shown that a flaxseed-supplemented diet decreases both the incidence and severity of ovarian cancer in laying hens, also induces CYP1A1 expression in liver.
Intensifying current transplant conditioning to remove rather than suppress immune cells ahead of autologous haematopoietic stem cell transplantation may result in long-term remission of multiple sclerosis, phase II trial findings show.
Ambry Genetics today announces that it is the first laboratory to provide CLIA-approved exome services for applications in clinical diagnostics. After comprehensive review by Ambry's staff of geneticists and medical directors, these results will allow clinicians to diagnose affected patients with conditions that have eluded traditional diagnostic approaches.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Douglas Arlyn Kinkel, MD Po Box 5719, Athens, GA 30604-5719 Ph: (706) 354-5770 | Douglas Arlyn Kinkel, MD 2450 S Telshor Blvd, Las Cruces, NM 88011-5069 Ph: (706) 354-5770 |
News Archive
The drug Hydroxychloroquine has long been studied as a treatment for malaria and autoimmune diseases. When the coronavirus pandemic spread across the globe, many countries resorted to using the drug in the hopes that it would improve outcomes of hospitalized patients affected by the coronavirus disease (COVID-19).
Gilead Sciences, Inc. today announced topline results from a Phase 3 clinical trial (Study GS-US-334-0118) in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin (RBV) for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection.
Oncotarget published "The pro-apoptotic actions of 2-methoxyestradiol against ovarian cancer involve catalytic activation of PKCδ signaling" which reported that the authors have previously shown that a flaxseed-supplemented diet decreases both the incidence and severity of ovarian cancer in laying hens, also induces CYP1A1 expression in liver.
Intensifying current transplant conditioning to remove rather than suppress immune cells ahead of autologous haematopoietic stem cell transplantation may result in long-term remission of multiple sclerosis, phase II trial findings show.
Ambry Genetics today announces that it is the first laboratory to provide CLIA-approved exome services for applications in clinical diagnostics. After comprehensive review by Ambry's staff of geneticists and medical directors, these results will allow clinicians to diagnose affected patients with conditions that have eluded traditional diagnostic approaches.
› Verified 2 days ago
Dr. Todd Leroy Lucas, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2450 S Telshor Blvd, Las Cruces, NM 88011 Phone: 706-354-5770 Fax: 706-354-5769 | |
William J Bussey, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4311 E Lohman Ave, Las Cruces, NM 88011 Phone: 505-532-8800 Fax: 505-532-5920 | |
Dr. Andrew Mark Wilke, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1930 Myrtle Ave, Las Cruces, NM 88001 Phone: 505-680-8226 | |
Thomas G Lemke, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 4311 E Lohman Ave, Las Cruces, NM 88011 Phone: 505-532-8800 Fax: 505-532-5920 | |
Marcey A. Gillespie, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2450 S Telshor Blvd, Las Cruces, NM 88011 Phone: 706-354-5770 Fax: 706-354-5769 | |
Kristy R. Ontiveros, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2450 S Telshor Blvd, Las Cruces, NM 88011 Phone: 706-354-5770 Fax: 706-354-5769 |